CASE REPORT

Opportunistic peritonitis in peritoneal dialysis: The example of *Paracoccus yeei*

Christelle Fosso1 | Evelyne Maillart2 | Bram Beun3 | Fahd Touzani1 | Bhavna Mahadeb4 | Philippe Clevenbergh2

1Nephrology Department, CHU Brugmann, Brussels, Belgium
2Internal Medicine Department, CHU St Pierre, Brussels, Belgium
3Laboratoire des Hôpitaux Universitaires de Bruxelles, Brussels, Belgium
4Infectious Diseases Department, CHU Brugmann, Brussels, Belgium

Correspondence
Philippe Clevenbergh, Internal Medicine Department, CHU St Pierre, Brussels, Belgium.
Email: philippe.clevenbergh@chu-brugmann.be

Abstract
*Paracoccus yeei*, a Gram-negative coccobacillus, is an emergent opportunistic pathogen. It originates from soil and water. VITEK and MALDI-TOF are used for identification. There are few reports of peritoneal dialysis peritonitis. Its presentation is usually indolent. It can be successfully treated with several antibiotics: β-lactams, aminoglycosides, without removing the catheter.

KEYWORDS
infectious diseases, nephrology

1 | INTRODUCTION

We report a case of *Paracoccus yeei* peritonitis in a patient undergoing automated peritoneal dialysis. Blood bottles inoculated with the dialysate grew a Gram-negative coccobacillus identified as *P yeei* by MALDI-TOF. The patient was successfully treated with a 3-week course of intraperitoneal amoxicillin after a transient shift to CAPD. The few reported cases of *P yeei* peritonitis show an indolent course. The microbe is susceptible to beta-lactams and aminoglycosides. It can be identified by VITEK (BioMerieux), MALDI-TOF, and 16 rRNA sequencing. Intrapерitoneally administered treatment is successful without catheter removal.

There are two modes of peritoneal dialysis: continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). Automated peritoneal dialysis is performed by a machine filling-in and emptying the belly during the night, with a fresh solution refill every morning. For CAPD, the patient must manually fill-in and empty his/her belly and exchanges are made at least four times during daytime. Infectious complications of peritoneal dialysis (PD) comprise peritonitis, catheter exit site, and tunnel infections. Over 0.5 episodes/patient-year rate of peritonitis has been reported in some facilities with up to 5% mortality rate. The biological definition of infectious PD peritonitis is effluent cell count with white blood cells (WBC) over 100/μL, with more than 50% PNM after a dwell time of least 2 hours. In 10%-20%, no etiological organism can be detected. This rate can be decreased by direct inoculation of dialysate in blood-culture bottles or amplification and identification of 16S rRNA. Some peritonitis may be truly aseptic. Skin colonizers such as *S epidermidis* and *S aureus*, Gram-negative organisms, or even fungus are involved owing to the mode of entry: skin and catheter-related, gut-associated translocation or hematogenous seeding. Various unexpected exogenous opportunistic micro-organisms originating from the patient's environment have been reported to cause exit site, tunnel infection, and peritonitis. *Paracoccus yeei* is an aerobic...
Gram-negative coccobacillus, found in soil and water. It can develop biofilms on plastic surface and has recently been identified as an opportunistic pathogen in human disease.\textsuperscript{6} Few cases of \textit{P yeei}-induced peritonitis in patients undergoing APD have been described.\textsuperscript{7-10} We report such a case successfully treated with intraperitoneal amoxicillin in a patient experiencing several episodes of exogenous catheter infections.

2 | CASE REPORT

A 50-year-old woman presented in September 2018 to the emergency department for diffuse abdominal pain with anorexia, diarrhea, and shivering for 4 days but was afebrile. She had been on APD since 07/2012 for the treatment of end-stage renal disease of unknown origin. Her medical history reveals chronic depression, social isolation, linguistic barrier, hypertension, and two previous episodes of APD peritonitis with removal followed by reinsertion of DP catheter. Laboratory analysis revealed the following: white blood cell count of 9.190/µL with normal differentiation and a C-reactive protein level: 47.7 mg/L (normal value: <10 mg/L). The peritoneal effluent looked cloudy. Effluent WBC was 2.111/µL with 1.598 neutrophils/µL, 49% PNM according to the machine. Another effluent sampled the next day showed 995 WBC/µl, with 53% PNM. The peritoneal catheter exit site was of normal appearance. Empirical treatment was initiated with intraperitoneal (IP) vancomycin (75 mg/L) and amikacin (12 mg/L) according to local guidelines. Incubated peritoneal fluid (Bactec Plus Aerobic; Becton Dickinson, Franklin Lakes, NJ, USA) yielded a positive culture for gram-negative cocci. These were identified as \textit{Paracoccus yeei} using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) (Bruker Daltonics, Bremen, Germany). Drug susceptibility was tested for ampicillin and amoxicillin-clavulanate, both of which were susceptible. Empiric treatment was discontinued on the second day of hospitalization and replaced by amoxicillin 150 mg IP per liter of dialysate. Antibiotic was administrated on CAPD, amoxicillin 250 mg per bags 3 times on a day at the beginning. During treatment, she was shifted to CAPD until the effluent WBC fall under 100/µL. There was no dry night nor dry day. When effluent WBC cells were under 100/µL, we restarted APD with 2 g of amoxicillin in the long dwell. The total treatment duration was 3 weeks. Subsequent effluent analyses showed a progressive decline and normalization of effluent cytology on the 9th day following diagnosis. However, the patient developed other catheter’s infections with \textit{S oralis, P mirabilis} involving the exit site, later \textit{P putida} and \textit{C freundii} peritonitis, and lastly a \textit{S pneumoniae} peritonitis in January 2020.

3 | DISCUSSION

The genus \textit{Paracoccus} compromises 17 species found in soil and brines. Only \textit{P yeei} has been identified as a pathogen causing disease in humans as it possesses specific genes of virulence.\textsuperscript{6} Infections with this opportunistic bacterium are rare and are mostly reported in immunocompromised patients. The case reports consist of a myocarditis in a heart transplant patient, peritonitis in PD, and bacteremia in a patient with cirrhosis.\textsuperscript{11-13} It is an exclusive aerobic, catalase and oxidase-positive, nonmotile Gram-negative (cocco)-bacillus, readily identified by the VITEK\textsuperscript{TM} 2 GN (BioMérieux), MALDI-TOF, or 16S rRNA sequencing using available reference databases. Previous reports have demonstrated antibiotic susceptibility to beta-lactams, fluoroquinolones, and aminoglycosides. In vitro, it is usually susceptible to most antibiotics including penicillins, cephalosporins, carbapenems, aminoglycosides, quinolones, and tetracyclines. However, as a Gram-negative coccobacillus, it is intrinsically resistant to vancomycin, a drug usually used as empirical therapy.\textsuperscript{9} We analyzed the reported cases of \textit{P yeei} associated DP peritonitis in Table 1. Presentation is usually mild with no fever and no or little abdominal pain. It affects patients with various degrees of immune suppression. Several treatments active on Gram-negative cocci have been applied. Treatment outcome is usually successful, without removing the DP catheter. Most of the patients are on APD. Amoxicillin and other beta-lactams are likely effective treatment options for \textit{P yeei}. Our patient received IP amoxicillin for 3 weeks. IP administration of antibiotics is the preferred route to treat peritonitis for a duration of 2−3 weeks according to the germ identified. IP dosing recommendations are available for many antibiotics.\textsuperscript{2} However, the antibiotic with the narrower spectrum of activity and the least toxicity should be preferred over others. The incidence of PD peritonitis varies greatly according to the reporting centers and ranges from 0.2 to over 0.5 episodes per patient/year.\textsuperscript{1} Various interventions are recommended to prevent catheter and tunnel infections. Skin/catheter-related exogenous infections can be prevented by general hygiene, patients’ education and training in practicing home PD, S. aureus decolonization, and antibiotic ointment of the exit site, among others.\textsuperscript{14} Endogenous, bacterial translocation-associated peritonitis can be prevented by avoidance of constipation, and antibio-prophylaxis prior to various invasive endoscopic procedures.\textsuperscript{15}

4 | CONCLUSION

Environmental germs of low virulence can cause peritoneal dialysis catheter-associated peritonitis providing opportunistic circumstances. We report a case of \textit{P yeei} PD peritonitis successfully treated with intraperitoneal amoxicillin in a
| Demography                  | Clinical manifestation | Biology                  | Peritoneal fluid analysis | Diagnostic method               | Treatment                                      | Outcome  | Ref. |
|-----------------------------|------------------------|--------------------------|---------------------------|--------------------------------|------------------------------------------------|----------|-----|
| 50-year-old female ESDR APD| Cloudy effluent        | WBC 9.190/µl             | WBC 2.11 l/µl             | Aerobic culture               | IP vancomycin + amikacin -> Amoxicillin         | cured    |     |
|                            | Apyretic               | CRP 47.7 mg/l            | PMN 49%                   | MALDI-TOF                     | 3 weeks                                        |          |     |
|                            | Abdominal pain         |                          |                           |                                |                                                |          |     |
| 25-year-old male ESRD APD  | Apyretic               | WBC 5.000/µl             | WBC 315/µl                | Gram Stain neg                | IP piperacillin + cephalothin ->?               | cured    | [7] |
|                            | Abdominal pain         | PMN 72%                  | PMN 75%                   | Aerobic culture/ BA + CA      |                                                |          |     |
|                            |                        | CRP 63 mg/l              |                            | VITEK 2 GN 16S rRNA sequencing|                                                |          |     |
| 46-year-old female ESRD APD| Cloudy effluent        | WBC 790 /µl              | Blood culture              | vancomycin and ceftazidine    | cured                                         |          |     |
|                            | Apyretic               | PMN 75%                  |                            | vancomycin and ceftazidine azidim |                                              |          |     |
|                            | Abdominal pain         |                          |                            | vancomycin and ceftazidine azidim |                                              |          |     |
|                            |                        |                          |                            | IP vancomycin and ceftazidine azidim |                                              |          |     |
|                            |                        |                          |                            | IP gentamicin + ceftazidine    | 2 weeks ambulatory                             |          |     |
|                            |                        |                          |                            | IP gentamicin + ceftazidine    | 2 weeks ambulatory                             |          |     |
| 81-year-old female Type II diabetes ESRD CAPD | Cloudy effluent | WBC 8.900 /µL, CRP 10.9 mg/L | WBC 105/µL                | Gram Stain neg                | IP gentamicin + vancomycin ->? Ambulatory       | cured    | [9] |
|                            | No fever               | PMN% not reported        | PMN% not reported         | Aerobic culture/ BA           | 2 weeks                                        |          |     |
|                            | No abdominal pain      |                          |                            | MALDI-TOF                     |                                                |          |     |
|                            |                        |                          |                            | 16S rRNA sequencing           |                                                |          |     |
| 51-year-old man ESRD Diabetes APD | Cloudy effluent | WBC 4.390/µl            | Gram Stain neg             | IV vancomycin + ceftazoxone  | cured                                         |          | [10]|
|                            | Apyretic               | PMN 84%                  | Conventional culture medium| IV vancomycin + ceftazoxone  | 3 weeks                                        |          |     |
|                            | No pain                |                          |                            | IV vancomycin + ceftazoxone  | 3 weeks                                        |          |     |
| 72-year-old male Diabetes HTA, ESRD APD | Cloudy effluent | WBC 6.700/µl            | WBC 350/µl                | Aerobic culture               | IP vancomycin 2 g (as he was previ-         | cured    | [16]|
|                            | Apyretic               | PMN 32%                  | PMN 32%                   | Difficulties in identification| ously colonized with MRSA) and gentamicin |          |     |
|                            | Abdominal pain         |                          |                            |                                | 50 mg                                          |          |     |
|                            |                        |                          |                            | IP vancomycin + gentamicin    |                                                |          |     |
|                            |                        |                          |                            | IP vancomycin + gentamicin    | 2 weeks                                        |          |     |

Abbreviations: ->, switched to; APD, automated peritoneal dialysis; BA, blood agar plates; CA, chocolate agar plates; CAPD, continuous ambulatory peritoneal dialysis; CRP, C-reactive protein; ESRD, End-stage renal disease; HTA, blood hypertension; IP, intraperitoneal route; IV, intravenous route; PMN, polymorphonuclear; WBC, white blood cells.
patient experiencing several episodes of infections with various germs. *P. yeei* shows sensitivity to various antimicrobials. This Gram-negative aerobic coccobacillus is now easily identified using VITEK or MALDI-TOF. Various prophylactic measures can be implemented to reduce the rate of PD-associated peritonitis from both exogenous and endogenous sources.

**ACKNOWLEDGMENTS**
Published with written consent of the patient.

**CONFLICT OF INTEREST**
None declared.

**AUTHOR CONTRIBUTIONS**
FC, BA, and TF: followed the case and reviewed the manuscript. ME: reviewed the manuscript. MB: identified the germ and reviewed the manuscript. CP: followed the case and organize the case reporting.

**ETHICAL STATEMENT**
The patient provided written informed consent to the publication of her case. Anonymity has been preserved.

**DATA AVAILABILITY STATEMENT**
The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ORCID**
Philippe Clevenbergh https://orcid.org/0000-0002-0522-9686

**REFERENCES**
1. Perl J, Fuller DS, Bieber BA, et al. Peritoneal dialysis-related infection rates and outcomes: results from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). *Am J Kidney Dis*. 2020;76(1):42-53. https://doi.org/10.1053/j.ajkd.2019.09.016
2. Salzer WL. Peritoneal dialysis-related peritonitis: challenges and solutions. *Int J Nephrol Renovasc Dis*. 2018;11:173-186. https://doi.org/10.2147/IJNRD.S123618
3. Pindi G, Kawle V, Rao Sunkara R, Satyanarayana Darbha M, Garikaparthi S. Continuous ambulatory peritoneal dialysis peritonitis: Microbiology and outcomes. *Indian J Med Microbiol*. 2020;38(1):72-77. https://doi.org/10.4103/ijmm.IJM_20_251
4. Mu H, Yang M, Zhang Y, et al. Pet-related Pasteurella multocida induced peritonitis in peritoneal dialysis: a case report and review of the literatures. *BMC Nephrol*. 2020;21(1):102. https://doi.org/10.1186/s12882-020-01765-1
5. Inoue H, Washida N, Morimoto K, et al. Non-tuberculous mycobacterial infections related to peritoneal dialysis. *Perit Dial Int*. 2018;38(2):147-149. https://doi.org/10.3747/pdi.2017.00172
6. Lasek R, Szuplewska M, Mitura M, et al. Genome Structure of the Opportunistic Pathogen *Paracoccus yeei* (Alphaproteobacterial) and Identification of Putative Virulence Factors. *Front Microbiol*. 2018;9:2553. https://doi.org/10.3389/fmicb.2018.02553
7. Wallet F, Blondiaux N, Foy CL, et al. *Paracoccus yeei*: a new unusual opportunistic bacterium in ambulatory peritoneal dialysis. *Int J Infect Dis*. 2010;14(2):e173-e174. https://doi.org/10.1016/j.ijid.2009.03.030
8. Sastre A, González-Arregoces J, Romainoik I, et al. *Paracoccus yeei* peritonitis in peritoneal dialysis. *Nefrologia*. 2016;36(4):445-446. https://doi.org/10.1016/j.nefro.2016.02.009
9. Arias MA, Clark J. *Paracoccus yeei* as a cause of peritoneal dialysis peritonitis in the United Kingdom. *IDCases*. 2019;15:e00486. https://doi.org/10.1016/j.idcr.2019.e00486
10. Nakayama T, Morimoto K, Uchiyama K. Peritoneal dialysis-related peritonitis caused by *Paracoccus yeei*. *Ther Apher Dial*. 2020. https://doi.org/10.1111/1744-9987.13604
11. Funke G, Frodl R, Sommer H. First comprehensively documented case of *Paracoccus yeei* infection in a human. *J Clin Microbiol*. 2004;42(7):3366-3368.
12. Schweiger M, Stiegler P, Scarpatetti M, et al. Case of *Paracoccus yeei* infection documented in a transplanted heart. *Transpl Infect Dis*. 2011;13(2):200-203.
13. Sack J, Peaper DR, Mistry P, et al. Clinical implications of *Paracoccus yeei* bacteremia in a patient with decompensated cirrhosis. *Malinis MIDCases*. 2016;7:9-10.
14. Szeto CC, Kam-Tao Li P, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 Update. *Perit Dial Int*. 2017;37(2):141-154. https://doi.org/10.3747/pdi.2016.00120
15. Wu H, Li I, Weng C, et al. Prophylactic antibiotics for endoscopy-associated peritonitis in peritoneal dialysis patients. *PLoS One*. 2013;8(8):e71532. https://doi.org/10.1371/journal.pone.0071532
16. Palamushingsam D, Tan K-S. The first case of *Paracoccus yeei* species infection in Australia causing peritonitis in an APD patient. *Nephrology*. 2014;19(2):116. https://doi.org/10.1111/nep.12167

How to cite this article: Fosso C, Maillart E, Beun B, Touzani F, Mahadeb B, Clevenbergh P. Opportunistic peritonitis in peritoneal dialysis: The example of *Paracoccus yeei*. *Clin Case Rep*. 2021;9:e04176. [https://doi.org/10.1002/ccr3.4176](https://doi.org/10.1002/ccr3.4176)